Testing a new eye drop to heal persistent corneal surface wounds

Plain-English translation of NCT07519902 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called , which is an eye drop designed to help heal persistent corneal epithelial defects — stubborn wounds on the clear front surface of your eye that haven't gotten better with standard treatments like lubricating drops or contact lenses. Half of the participants will receive the medication, and half will receive a placebo (inactive) eye drop, so researchers can compare how well the treatment works. The study will track whether the medication helps your cornea heal completely over 16 weeks of treatment, plus an additional 24 weeks of follow-up.

Some people develop corneal surface wounds that don't heal on their own, even after trying regular treatments. This medication is designed to stimulate the natural healing process of the cornea, offering hope for people whose eyes haven't responded to conventional care.

Do you qualify?

You likely qualify if…

you are at least 18 years old (19 or older in South Korea)
you have a persistent corneal surface wound that is at least 1.0 mm across and has not healed for at least 14 days despite standard treatments
you have already tried at least one conventional treatment (such as lubricating drops, stopping preserved eye medications, or wearing a bandage contact lens) without success
your other eye has useful vision (not complete vision loss)
you are willing to keep any other eye medications you're taking at a stable dose throughout the study

You likely don't qualify if…

you have an active infection or significant inflammation in the affected eye at the time of screening
your cornea has severe thinning (more than 30% thinner than normal) or shows signs of deep tissue damage beyond the surface
you have severe eyelid problems that directly affect the wound, such as severe drooping, inability to fully close your eye, or abnormal eyelid position
you have advanced end-stage eye surface disease, such as severe stem cell damage or scarring of the conjunctiva
you have previously received cenegermin or other experimental wound-healing eye drops

What participation looks like

You will visit the study clinic multiple times over 40 weeks. During the first 16 weeks, you'll receive either the new medication or a placebo eye drop and apply it as directed (you won't know which one you're getting). At clinic visits, doctors will examine your eye carefully, take photographs, and monitor whether the corneal wound is healing. After 16 weeks of treatment, you'll continue coming back for follow-up visits over the next 24 weeks so researchers can see if the healing lasts and check for any side effects. Throughout the study, you can continue taking other eye medications you may already be using.

AI-generated summary from trial data · Sep 11, 2026 · Not medical advice

Trial locations(77 sites)

United States

Azul Vision, INC, Huntington Beach, California

Harvard Eye Associates, Laguna Hills, California

Loma Linda University Adventist Health Sciences Center, Loma Linda, California

UCLA - Jules Stein Eye Institute (JSEI) - Diabetic Eye Dise, Los Angeles, California

California Eye Specialists Medical Group, Inc., Redlands, California